The IND is what convinces the FDA your drug is safe enough to put into people. brings your manufacturing, toxicology, and first protocol together into one case.
Fast Track mainly buys access: more frequent meetings, more written feedback, and the ability to submit your marketing application on a rolling basis, in pieces as they are ready, rather than all at once at the end. It is the earliest expedited program you can qualify for.
A higher bar than Fast Track and a bigger payoff. This is FDA’s extra love. Senior staff, hands on guidance, and a development plan shaped with the Agency. It takes preliminary clinical evidence to qualify.
Type A restarts a stalled program, usually after a hold or a complete response letter. Type B covers the milestones: pre-IND, end of Phase 2, pre-NDA. Type C is everything else. Type D is one narrow question with a fast turnaround. Which type you request, and how you frame the questions, is what determines whether you get an answer worth having.
The Orphan Products Clinical Trials Grants Program funds trials directly. You need an active IND at the time of award, and it’s open to organizations anywhere in the world, for-profit included.
The FDA has to agree the endpoint is reasonably likely to predict real benefit, and you commit to a confirmatory trial afterwards. That agreement is the entire job, and it’s won in the meetings rather than in the application. Done well, it takes years off the path to market.
Most programs move through all three stages. We can guide the whole program from here, or pick up wherever yours already stands.
Years in orphan drug regulatory affairs
Orphan drug designations decided at FDA by Dr. Cote
Designation applications written by Dr. Cote
Clients guided worldwide
We're brick-and-mortar in Cambridge, Massachusetts, but reachable from anywhere, anytime.
Dr. Cote directed the FDA's Office of Orphan Products Development. We know how reviewers read a submission, including the unwritten rules.
We do not take regulatory work for common diseases. Every program we accept is a rare disease program. That is the only kind of work we do, and it is the reason we do it well.
Fast Track can be granted on nonclinical data and mainly buys you access and a rolling submission. Breakthrough needs preliminary clinical evidence that your drug beats what's available, and brings the FDA's senior staff onto your development plan. Many programs get Fast Track first and Breakthrough later.
It depends on what you're asking and when. Type B for the milestones, Type A if the program is stalled, Type D for a single narrow question. Choosing wrong costs months, so it's worth a conversation before you submit the request.
Yes. The program is open to public, private, nonprofit and for-profit organisations anywhere in the world. You need an active IND at the time of award.
A hold pauses your trial until the FDA's questions are answered. We resolve it through the same channel used to prevent it, usually a Type A meeting.
Not for Fast Track, it can be based on nonclinical data alone. Breakthrough needs preliminary clinical evidence, so you'll typically already be in trials.